Mandate

Vinge is advising Nytida in connection with merger with the Solhaga Group

January 25, 2016

Vinge is advising Nytida, which is part of Ambea, in connection with the merger with Solhagagruppen (the “Solhaga Group”).

Nytida intends to merge with the Solhaga Group. Nytida and the Solhaga Group possess considerable experience and expertise within the fields of functional impairment and the Solhaga Group specializes in the fields of neuropsychiatric and psychiatric impairment and reduced development. Both Nytida and the Solhaga Group conduct operations throughout a large part of Sweden and provide accommodation, schooling, short-term accommodation and daytime activities. The Solhaga Group also conducts operations in Norway.

Closing of the transaction is subject to the customary approval of the relevant competition authority.

Vinge’s team consisted of, among others, partners Christina Kokko, Jonas Johansson, Louise Brorson Salomon and Marcus Glader together with associates Linda Sengul, Maria Dahlin, Albert Wållgren, Anna-Maria Terzi, Emil Fahlén Godö and Anne Wijkman.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025